One Small Step Towards Personalized Medicine: CMS Reimbursement Changes in “Doc Fix”
This article was originally published in RPM Report
Executive Summary
CMS is emphasizing coverage of companion diagnostics as a key role it can play in advancing personalized medicine. A couple of add-ons to this year’s “Doc Fix” legislation may help move that effort forward.
You may also be interested in...
The Companion Diagnostics Dilemma
An Institute of Medicine workshop on companion diagnostics suggests that regulatory standards are evolving at FDA to encourage companion diagnostic development. But almost everything else is still a challenge.
US FDA Alzheimer Guidance Update Reflects Changes In Biomarkers – And Leadership
Latest update to draft guidance on early Alzheimer’s drug development is the third iteration of a document first published in 2013. The history of the guidance is a reflection of structural and leadership changes in the neurology review team at FDA.
Biden’s Co-Pay Cap Is Silver Lining For Pharma In Drug Pricing Campaign
President Biden’s call to expand the US Medicare price negotiation program is naturally making headlines from his campaign-year State of the Union Address. But his call for a national cap on co-pays could be an important opportunity for industry in the years to come.